TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04367636

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral: OCAT-sham
Description: Placebo version of the online contingent attention training preceded by psycho-education movieclip.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: OCAT
Description: Online contingent attention training preceded by psycho-education movieclip.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: psycho-education video
Description: Both groups get to see a psycho-education video before the smartphone training starts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psycho-education video
Description: Both groups get to see a psycho-education video before the smartphone training starts.
Study: NCT03908697

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mira monitor comparison to ClearBlue monitor
Description: Testing first morning urine with hormone test sticks at home
Study: NCT03405129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phoenix
Description: Phoenix cessation app

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phoenix
Description: Phoenix cessation app

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NRT order button
Description: Ability to order NRT through smartphone app

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Factoid
Description: Factoid app
Study: NCT04206501

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic ICD with Opti Vol-Monitor
Description: Physiologic and functional data from Cardiac Implantable Electronic Devices (CIEDs), including information on heart rate, activity, and fluid status derived from the OptiVol monitor, together with a concurrent patient engagement strategy through remote interactions, can be used to optimize the medical management of HF patients implanted with an ICD.
Study: NCT02555072

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: yellow fever vaccine
Description: yellow fever vaccination in naive individuals who leaves in a state where this type of vaccination is not recommendated
Study: NCT04691505

Intervention type: DRUG
Intervention: Methotrexate
Description: Methotrexate is used as the reference group.

Intervention type: DRUG
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine is used as the exposure group.
Study: NCT02868320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS messages
Description: Daily educational messages addressing the following categories: diet, exercise, complications, medications, foot care, blood sugar testing, and hypo- and hyperglycemia.~Weekly reminder messages of blood glucose testing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instruction booklet
Description: General detailed instructions addressing the same SMS categories.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instruction booklet
Description: General detailed instructions addressing the same SMS categories.
Study: NCT01580618

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Injection of 60 ml normal saline twice a day for three days using the existing chest tube.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNK (Tenecteplase)
Description: Injection of 4 mg of TNK with 59 ml normal saline into the existing chest tube twice a day for three days.
Study: NCT02824770

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol HCl (Tramosel®) via PCA system (Gemstar®)
Description: Patients will receive infusion of Tramadol HCl (Tramosel®) via patient-controlled analgesia system (Gemstar®)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Major abdominal surgery
Description: Any major abdominal surgery (e.g. colectomy, gastrectomy)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Major abdominal surgery
Description: Any major abdominal surgery (e.g. colectomy, gastrectomy)
Study: NCT04645654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Three sessions of 30 minute hypnosis, based on standardised script, focused on pain management.
Study: NCT00694889

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer games
Description: The control treatment involves commercially available computer games that participants will practice 1 hour per day, 5 days per week, for 16 weeks.
Study: NCT02660294

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platlet rich plasma
Description: Platelet-rich plasma (PRP) is prepared from fresh whole blood which is collected from a peripheral vein, stored in acid citrate dextrose solution A (ACD-A) anticoagulant and processed to increase platelets by separating various components of blood
Study: NCT03019835

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine (40 mcg / kg) at different time of neuromuscular block's recovery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine (40 mcg / kg) at different time of neuromuscular block's recovery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine (40 mcg / kg) at different time of neuromuscular block's recovery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine (40 mcg / kg) at different time of neuromuscular block's recovery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spontaneous recovery
Description: just measuring the Train Of Four at 3 6 9 12 and 15 minutes and measure the Train Of Four Ratio
Study: NCT02978716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: G1T28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: G1T28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin
Study: NCT01511159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Single dose of 6 mcg/kg by inhalation. Progression to open-label trial part will be based on safety data

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single dose by inhalation. Progression to open-label trial part will be based on safety data

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Single dose of 12 mcg/kg by inhalation. Subjects receive treatment in random order

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Single dose 6 mcg/kg injected subcutaneously. Subjects receive treatment in random order

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin human
Description: Single dose 0.4 IU/kg by inhalation. Subjects receive treatment in random order
Study: NCT01143363

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: resting - control

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity intermittent training
Study: NCT01511159

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin human
Description: Single dose 0.08 IU/kg injected subcutaneously. Subjects receive treatment in random order

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 24 mcg/kg by inhalation. Progression to dose level will be based on safety evaluation
Study: NCT03307694

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: All ultrasound images will be acquired by an in-house ultrasound technologist using a Verasonics Vantage (Verasonics Inc., Kirkland, Washington, USA) ultrasound system. During imaging, the technologist will position the Verasonics transducer, under b-mode guidance, in planes overlying the thyroid nodules approximating those obtained during previous clinical ultrasound scans.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: All ultrasound images will be acquired by an in-house ultrasound technologist using a Verasonics Vantage (Verasonics Inc., Kirkland, Washington, USA) ultrasound system. During imaging, the technologist will position the Verasonics transducer, under b-mode guidance, in planes overlying the thyroid nodules approximating those obtained during previous clinical ultrasound scans.

Intervention type: DIAGNOSTIC_TEST
Intervention: Shear wave elasticity imaging
Description: Shear wave elasticity imaging (SWEI) is obtained during the standard ultrasound session. The generation of shear wave images consists of two important steps called pushing and tracking. First, in the pushing mode, a long focused ultrasound beam is transmitted to perturb tissue, generating ultrasonic shear waves in tissue that propagate perpendicular to the direction of pushing. In the tracking mode, shear wave propagation is observed and recorded. Because the speed of shear waves is a function of Young's modulus, these data reveal information about the stiffness of underlying biological tissue.

Intervention type: DIAGNOSTIC_TEST
Intervention: Shear wave elasticity imaging
Description: Shear wave elasticity imaging (SWEI) is obtained during the standard ultrasound session. The generation of shear wave images consists of two important steps called pushing and tracking. First, in the pushing mode, a long focused ultrasound beam is transmitted to perturb tissue, generating ultrasonic shear waves in tissue that propagate perpendicular to the direction of pushing. In the tracking mode, shear wave propagation is observed and recorded. Because the speed of shear waves is a function of Young's modulus, these data reveal information about the stiffness of underlying biological tissue.

Intervention type: DIAGNOSTIC_TEST
Intervention: Multi-angle compound shear wave elasticity imaging
Description: The multi-angle compound SWEI (MAC-SWEI) algorithm, which generates shear images based on multiple angled push beams, has the potential to generate more accurate shear wave images in the context of thyroid imaging. To assess the MAC-SWEI technique, shear wave images will be used to generate estimates of the relative stiffness of lesions via their normalized Young's modulus.
Study: NCT03329612

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Remote Ischemic Preconditioning
Description: Serial inflations and deflations as detailed in the arm/group descriptions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning
Description: Serial inflations and deflations as detailed in the arm/group descriptions.
Study: NCT03869970

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: REST
Description: The REST group will be recommended to return to school and light physical and cognitive activity as soon as tolerated- but no sooner than 48 hrs post-injury per current consensus recommendations. Notifications from the Fitbit app will be turned off, and step goal will be set at 500, to minimize positive feedback and reminders from achievement of activity goals

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACTIVITY
Description: ACTIVITY group will be encouraged to engage in light to moderate physical activity with the goal of reaching 10,000 steps a day for one or more days during the first week. Subjects will be encouraged to engage in low-risk activities (e.g. walking). Subjects will be instructed to avoid activities that may increase risk of re-injury (e.g. bike riding, climbing, trampoline, sports). Fitbit notifications will be turned on and step goals will be set at 10,000. The simple goal of reaching 10,000 steps is clear to patients regardless of health literacy level, and real-time feedback provides continuous motivation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACTIVITY
Description: ACTIVITY group will be encouraged to engage in light to moderate physical activity with the goal of reaching 10,000 steps a day for one or more days during the first week. Subjects will be encouraged to engage in low-risk activities (e.g. walking). Subjects will be instructed to avoid activities that may increase risk of re-injury (e.g. bike riding, climbing, trampoline, sports). Fitbit notifications will be turned on and step goals will be set at 10,000. The simple goal of reaching 10,000 steps is clear to patients regardless of health literacy level, and real-time feedback provides continuous motivation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mHEALTH
Description: mHEALTH group will be instructed to download the SuperBetter© app. In addition to the pre-programmed general resilience goals, research assistants will help the subjects to set personal mental, social, and emotional rehabilitation goals and milestones for acute recovery from mTBI (e.g. return to school for ½ the day, have an improvement in symptoms). These goals/milestones will give the patient an opportunity to celebrate the achievement of improvement from mTBI with the goal of generating a positive contextual frame for recovery.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mHEALTH
Description: mHEALTH group will be instructed to download the SuperBetter© app. In addition to the pre-programmed general resilience goals, research assistants will help the subjects to set personal mental, social, and emotional rehabilitation goals and milestones for acute recovery from mTBI (e.g. return to school for ½ the day, have an improvement in symptoms). These goals/milestones will give the patient an opportunity to celebrate the achievement of improvement from mTBI with the goal of generating a positive contextual frame for recovery.
Study: NCT01143363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short sprint
Study: NCT04160286

Intervention type: OTHER
Intervention: Electroconvulsive therapy
Description: Electroconvulsive therapy is a procedure, done under general anesthesia, in which small electric currents are passed through the brain, intentionally triggering a brief seizure.~Repeated as deemed needed by the patients' doctor. Typically prescribed 10 times (3 times pr week)
Study: NCT02040350

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pralidoxime
Description: Pralidoxime was compared to placebo to study the effects of the drug on mortatlity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pralidoxime
Description: Pralidoxime was compared to placebo to study the effects of the drug on mortatlity
Study: NCT01694121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MEN Count
Description: The MEN Count model integrates HIV risk reduction and gender-equity counseling with housing and employment case management via multiple one-on-one sessions delivered by a peer case manager over 60-90 day period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison
Description: general health intervention for men, not inclusive of HIV or relationship health
Study: NCT01877486

Intervention type: PROCEDURE
Intervention: Ablation
Description: Pulmonary vein isolation following dofetilide
Study: NCT00980512

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training
Description: 16 weeks of parent training led by trained group facilitator
Study: NCT02113267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: 4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals (9) with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
Study: NCT04402736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The modified Barthel Index-based rehabilitation nursing program
Description: The intervention with the program based on the MBI classified function of patients into five levels, with every 20 points as a level, Each level corresponds to different training items. Training items included self-care training and training in transfer activities, sitting balance, walking, and sit-to-stand, etc. Each training session lasting at least 30 minutes, two sessions per day, for seven continuous days. During the intervention, the rehabilitation therapist's conventional treatment is not interfered.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual care
Description: Patients in the control group received clinical usual care including the activities of daily living assessment, early mobilization guide and health education. During the intervention, the rehabilitation therapist's conventional treatment is not interfered.
Study: NCT02130557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Bosutinib (Bosulif®) is an orally bioavailable, potent, multi-targeted, dual Src-Abl tyrosine kinase inhibitor (TKI) that has been approved for the treatment of adult patients with Philadelphia positive (Ph+) chronic phase (CP), accelerated phase (AP) and blast phase (BP) chronic myelogenous leukemia (CML) previously treated with other TKI inhibitor therapy.\[1\] This study will investigate the use of bosutinib as first-line treatment for patients with Ph+ CP CML.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Imatinib mesylate (referred to in this protocol as imatinib) is an inhibitor of the BCR-ABL kinase and been the standard first-line therapy for patients with chronic-phase CML. Imatinib was granted approval by the European Commission in November 2001 and by the FDA in December 2002 for the treatment of newly diagnosed patients with CP Ph+ CML based on results from the IRIS trial.~Imatinib is considered the standard of care for both first-line and later line settings, and consequently is an appropriate active comparator.
Study: NCT01357694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychotherapeutic contacts
Description: psychotherapeutic contacts during inpatient hospital stay and up to 3 months outpatient appointments after discharge
Study: NCT03160521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone ISM 75 mg
Description: Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone ISM 100 mg
Description: Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Risperidone ISM
Description: Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
Study: NCT02134262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide or Bendamustine
Description: Cyclophosphamide \[1.5 g/m\^2 x 1 day Intravenous (IV)\] or Bendamustine \[120 mg/m\^2 x 2 days Intravenous (IV)\] is administered as Pre-treatment medication of CD19-CAR-T.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide or Bendamustine
Description: Cyclophosphamide \[1.5 g/m\^2 x 1 day Intravenous (IV)\] or Bendamustine \[120 mg/m\^2 x 2 days Intravenous (IV)\] is administered as Pre-treatment medication of CD19-CAR-T.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide or Bendamustine
Description: Cyclophosphamide \[1.5 g/m\^2 x 1 day Intravenous (IV)\] or Bendamustine \[120 mg/m\^2 x 2 days Intravenous (IV)\] is administered as Pre-treatment medication of CD19-CAR-T.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide or Bendamustine
Description: Cyclophosphamide \[1.5 g/m\^2 x 1 day Intravenous (IV)\] or Bendamustine \[120 mg/m\^2 x 2 days Intravenous (IV)\] is administered as Pre-treatment medication of CD19-CAR-T.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Dose Level -1
Description: CD19-CAR-T \[1 x 10\^5 cells/kg x 1 day and 2 x 10\^5 cells/kg x 1 day Intravenous (IV)\] are administered.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Dose Level 1
Description: CD19-CAR-T \[1/3 x 10\^6 cells/kg x 1 day and 2/3 x 10\^6 cells/kg x 1 day Intravenous (IV)\] are administered.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Dose Level 2
Description: CD19-CAR-T \[1 x 10\^6 cells/kg x 1 day and 2 x 10\^6 cells/kg x 1 day Intravenous (IV)\] are administered.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Dose Level 3
Description: CD19-CAR-T \[1/3 x 10\^7 cells/kg x 1 day and 2/3 x 10\^7 cells/kg x 1 day Intravenous (IV)\] are administered.
Study: NCT03878381

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Skin Care Cream
Description: The skin care regimen we will be testing includes ingredients such Hyaluronic acid 1%, Vitamin E Acetate, Vitamin A Acetate, Co-enzyme Q 10, L-Arginine, L-glutamine, Phytonadione, Argireline Peptide solution, GABA, Vitamin C, glycolic acid, and Fenugreek.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be a formula with no active ingredients
Study: NCT01700998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04190381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FR-Mask
Description: The investigational medical product of this study is a biomedical repair mask, FR-MASK, acting like moisturizing lotion applied on breasts.~The FR-Mask is applied to users' radiation-irritated breast skin for 15 to 20 minutes every 3 days.
Study: NCT01997632

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: a single dose of monovalent high-dose inactivated poliovirus type 2 vaccine (m-IPV2 HD)
Description: a single dose m-IPV2 HD (study vaccine), 0,5ml
Study: NCT02139878

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wild blueberry juice

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo wild blueberry juice
Study: NCT04328753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Super Oxide water
Description: Microsafe®, a recently available super-oxidized solution for gingival care, offers a completely improved approach for treatment of gingivitis. The neutral pH, super oxidized water was certified as an antiseptic .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: CHX is a regular bisbiguanide artificial antiseptic containing of two biguanide groups and four chlorophenyl rings linked by a hexamethylene bridge. The dicationic nature of CHX makes it interacting strongly with anions, which is related to its safety, efficacy, and side effects. It is available in three forms, digluconate, acetate and hydrochloride salts. CHX has broad spectrum antimicrobial activity

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water
Description: act as a negative control in this study